Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer
Climb Bio (NASDAQ:CLYM), a clinical-stage biotechnology company, has appointed Susan Altschuller, Ph.D., MBA as Chief Financial Officer. Dr. Altschuller brings over 20 years of strategic and financial leadership experience, notably serving as CFO of Cerevel Therapeutics until its $8.7B AbbVie acquisition and as CFO of ImmunoGen.
As part of her appointment, Dr. Altschuller received an inducement equity award of 600,000 stock options with a ten-year term, vesting over four years. The company is advancing two key programs, budoprutug and CLYM116, with significant clinical data expected in the coming year.
Climb Bio (NASDAQ:CLYM), una empresa biotecnológica en etapa clínica, ha designato Susan Altschuller, Ph.D., MBA como Chief Financial Officer. La Dra. Altschuller aporta más de 20 años de experiencia en liderazgo estratégico y financiero, destacando su labor como CFO de Cerevel Therapeutics hasta su adquisición de 8.7 mil millones de dólares por AbbVie y como CFO de ImmunoGen.
Como parte de su nombramiento, la Dra. Altschuller recibió una asignación de acciones de inducción de 600,000 opciones sobre acciones con un plazo de diez años, con vesting a lo largo de cuatro años. La compañía está avanzando en dos programas clave, budoprutug y CLYM116, con datos clínicos significativos esperados en el próximo año.
Climb Bio (NASDAQ:CLYM), una empresa de biotecnología en etapa clínica, ha designado a Susan Altschuller, Ph.D., MBA como directora financiera. La Dra. Altschuller aporta más de 20 años de experiencia en liderazgo estratégico y financiero, destacando como CFO de Cerevel Therapeutics hasta su adquisición por AbbVie de 8.7 mil millones de dólares y como CFO de ImmunoGen.
Como parte de su nombramiento, la Dra. Altschuller recibió una asignación de acciones de inducción de 600,000 opciones sobre acciones con un plazo de diez años, con vesting durante cuatro años. La compañía está avanzando en dos programas clave, budoprutug y CLYM116, con datos clínicos significativos esperados en el próximo año.
Climb Bio (NASDAQ:CLYM), 임상 단계 생명공학 회사는 Susan Altschuller, Ph.D., MBA를 최고재무책임자(CFO)로 임명했습니다. 알츠쵀ller 박사는 20년이 넘는 전략적 및 재무 리더십 경험을 보유하고 있으며, 특히 Cerevel Therapeutics의 CFO로 재직하다가 AbbVie에 의해 87억 달러에 인수된 이후와 ImmunoGen의 CFO로 재직한 바 있습니다.
임명에 따라 알츠쵀ller 박사는 10년의 기간을 갖는 600,000주 주식 매수선택권의 유도 보상(인듀스먼트 주식 보상)을 받았으며, 4년에 걸쳐 가속 vesting됩니다. 회사는 budoprutug와 CLYM116의 두 가지 핵심 프로그램을 진행 중이며, 내년에는 중요한 임상 데이터가 기대됩니다.
Climb Bio (NASDAQ:CLYM), une société biotechnologique en phase clinique, a nommé Susan Altschuller, Ph.D., MBA au poste de directrice financière. La Dr. Altschuller apporte plus de 20 ans d’expérience en leadership stratégique et financier, notamment en tant que CFO de Cerevel Therapeutics jusqu’à son acquisition par AbbVie pour 8,7 milliards de dollars et en tant que CFO d’ImmunoGen.
Dans le cadre de cette nomination, la Dr. Altschuller a reçu une attribution d’actions d’induction de 600 000 options sur actions avec une durée de dix ans, le vesting s’effectuant sur quatre ans. L’entreprise avance sur deux programmes clés, budoprutug et CLYM116, avec des données cliniques significatives attendues au cours de l’année prochaine.
Climb Bio (NASDAQ:CLYM), ein klinisch fases Biotechnologieunternehmen, hat Susan Altschuller, Ph.D., MBA als Chief Financial Officer (CFO) ernannt. Frau Dr. Altschuller bringt mehr als 20 Jahre an strategischer und finanzieller Führungserfahrung mit, insbesondere als CFO von Cerevel Therapeutics bis zu seiner 8,7-Milliarden-Dollar-Übernahme durch AbbVie und als CFO von ImmunoGen.
Im Rahmen ihrer Ernennung erhielt Dr. Altschuller eine Anreiz-Aktienoptionszuteilung von 600.000 Optionen mit einer Laufzeit von zehn Jahren, vesting über vier Jahre. Das Unternehmen treibt zwei wichtige Programme voran, budoprutug und CLYM116, und erwartet im kommenden Jahr signifikante klinische Daten.
Climb Bio (NASDAQ:CLYM)، شركة تقنيات حيوية في مرحلة مخبرية، عيّنت سوزان ألتشولر، دكتوراة في الفلسفة، ماجستير في إدارة الأعمال كمدير مالي. تتمتع الدكتورة ألتشولر بأكثر من 20 عامًا من الخبرة في القيادة الاستراتيجية والمالية، بما في ذلك عملها كمدير مالي لشركة Cerevel Therapeutics حتى عملية الاستحواذ من قبل AbbVie بقيمة 8.7 مليار دولار وبصفته CFO في ImmunoGen.
كجزء من تعيينها، تلقت الدكتورة ألتشولر منحة أسهم حوافز قدرها 600,000 خيار أسهم لمدة عشر سنوات، مع vesting على مدى أربع سنوات. تقود الشركة حالياً برنامجين رئيسيين، budoprutug و CLYM116، مع توقع بيانات إكلينيكية مهمة في العام القادم.
Climb Bio (NASDAQ:CLYM)，一家处于临床阶段的生物技术公司，任命 Susan Altschuller, Ph.D., MBA 为首席财务官。Altschuller 博士拥有超过 20 年的战略与财务领导经验，曾任 Cerevel Therapeutics 的 CFO，直至其被 AbbVie 以 87 亿美元收购，以及 ImmunoGen 的 CFO。
作为任命的一部分，Altschuller 博士获得了一项诱导性股权奖励，600,000 份股票期权，期限为十年，四年内开始归属。公司正在推进两个关键项目 budoprutug 和 CLYM116，预计在来年获得重要临床数据。
- Appointment of experienced CFO with strong track record in biotech acquisitions and commercial launches
- Multiple clinical readouts expected in the coming year for both pipeline programs
- Significant leadership experience from successful biotech companies including Cerevel ($8.7B acquisition) and ImmunoGen
- Substantial stock option grant of 600,000 shares represents potential future dilution
- Company still in clinical-stage with no commercial products
WELLESLEY HILLS, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with the addition of Susan Altschuller, Ph.D., MBA, as Chief Financial Officer. Susan brings over two decades of strategic and financial leadership experience.
“Susan is a seasoned biopharmaceutical leader with a strong track record in financial strategy, capital allocation, and operational execution, and we are delighted to welcome her to our team,” said Aoife Brennan, President and CEO of Climb Bio. “Our company is making excellent progress advancing budoprutug and CLYM116, and during the year ahead, we expect to generate meaningful clinical data from both programs that will guide our path forward. Susan’s financial and strategic expertise will be of tremendous value as we advance our pipeline and work to maximize the potential of our investigational therapeutics.”
Dr. Altschuller is an accomplished senior executive with extensive biopharmaceutical leadership experience. She served as the Chief Financial Officer of Cerevel Therapeutics until its
“I am inspired by the vision of Climb Bio and the potential of its pipeline to address serious immune-mediated diseases,” said Susan Altschuller, incoming Chief Financial Officer of Climb Bio. “It is an honor to join the team at such an important time. As Climb Bio approaches multiple clinical readouts, I look forward to supporting the advancement of the company’s therapeutic portfolio as we seek to create both long-term value for shareholders and more inspired medicines for patients.”
In connection with her appointment, Climb Bio has granted an inducement equity award to Dr. Altschuller, pursuant to Climb Bio’s 2025 Inducement Plan, as an inducement material to Dr. Altschuller’s acceptance of employment with Climb Bio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity award was granted effective October 1, 2025 and consisted of a non-statutory stock option to purchase up to an aggregate of 600,000 shares of common stock of Climb Bio with an exercise price equal to the closing price per share of Climb Bio’s common stock as reported by The Nasdaq Global Market on October 1, 2025. In addition, the option has a ten-year term and vests over four years, with
About Climb Bio, Inc.
Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s pipeline includes budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody being developed for IgA nephropathy. For more information, please visit climbbio.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding: future expectations, plans and prospects for Climb Bio; expectations regarding the therapeutic benefits, clinical potential and clinical development of budoprutug and CLYM116; expectations regarding the timing of submitting an investigational new drug application or clinical trial application submission for CLYM116; the anticipated timelines for initiating a clinical trial of CLYM116; the anticipated timelines for announcing data from Climb Bio’s ongoing and planned clinical trials; and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” “will,” “working” and similar expressions. Forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. Climb Bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with: the ability of Climb Bio to timely and successfully achieve or recognize the anticipated benefits of its acquisition of Tenet Medicines, Inc. and its technology transfer and exclusive license agreement with Beijing Mabworks Biotech Co., Ltd.; changes in applicable laws or regulation; the possibility that Climb Bio may be adversely affected by other economic, business and/or competitive factors; Climb Bio’s ability to advance budoprutug and CLYM116 on the timelines expected or at all and to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data safety monitoring boards; replicating in clinical trials positive results found in early-stage clinical trials; competing successfully with other companies that are seeking to develop treatments for primary membranous nephropathy, immune thrombocytopenia, systemic lupus erythematosus, IgA nephropathy and other immune-mediated diseases; maintaining or protecting intellectual property rights related to budoprutug, CLYM116 and/or its other product candidates; managing expenses; and raising the substantial additional capital needed, on the timeline necessary, to continue development of budoprutug, CLYM116 and any other product candidates Climb Bio may develop. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Climb Bio’s actual results to differ materially from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in Climb Bio’s most recent filings with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Climb Bio’s views as of the date hereof and should not be relied upon as representing Climb Bio’s views as of any date subsequent to the date hereof. Climb Bio anticipates that subsequent events and developments will cause Climb Bio’s views to change. However, while Climb Bio may elect to update these forward-looking statements at some point in the future, Climb Bio specifically disclaims any obligation to do so, except as required by law.
Investors and Media
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
FAQ
Who is the new CFO of Climb Bio (NASDAQ:CLYM)?
What is Susan Altschuller's previous experience before joining Climb Bio?
What compensation package did Climb Bio (CLYM) offer to Susan Altschuller?
What are Climb Bio's main pipeline programs in development?
What type of company is Climb Bio (NASDAQ:CLYM)?
